89Zr-LNCab072

89Zr-LNCab072 is a radiolabeled monoclonal antibody developed for PET imaging of HER2-positive cancers. It consists of a HER2-targeting antibody labeled with the radioactive isotope zirconium-89 (^89Zr), enabling non-invasive imaging of HER2 expression in tumors. This agent is under early-phase clinical evaluation for its ability to detect and characterize HER2-positive malignancies, including breast cancer, gastric cancer, and urothelial carcinoma, using PET/CT imaging. The primary objectives include assessing efficacy, safety, dosimetry, biodistribution, and diagnostic performance in comparison to traditional tracers such as 18F-FDG[1][3].